Search | Clinical Trials Finder

Conditions: HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
Interventions: Prevnar-13; Biological
Lead sponsor: VA Eastern Colorado Health Care System; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections, Histoplasmosis, Blastomycosis
Interventions: Itraconazole, Amphotericin B; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more

Conditions: Sexually Transmitted Diseases, Bacterial
Interventions: Doxycycline Pill; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bacterial Vaginosis, Vaginal Microbiome, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginitis
Interventions: Menstrual Cup; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 15 Years to 35 Years · Female only
Enrollment: 408 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections, Syphilis
Interventions: Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland

Conditions: Candidiasis, Oral, Eating Disorders, HIV Infections, Speech Disorders
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tuberculosis, HIV Infections
Interventions: rifabutin, isoniazid, efavirenz; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Ethambutol hydrochloride, Clarithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 8
States / cities: Tucson, Arizona • Baltimore, Maryland • Camden, New Jersey + 5 more

Conditions: HIV Infections, Tuberculosis
Interventions: Nelfinavir, Rifabutin; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 0 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 20
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more

Conditions: HIV Infections, Histoplasmosis
Interventions: Itraconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 8
States / cities: Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 5 more

Conditions: Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection
Interventions: NeuMoDx CT/NG Assay, FDA-cleared NAATs; Diagnostic Test
Lead sponsor: NeuMoDx Molecular, Inc.; Industry
Eligibility: 14 Years to 80 Years
Enrollment: 4,017 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • North Miami, Florida • Orlando, Florida + 12 more

Conditions: HIV Infections, Pneumococcal Infections
Interventions: Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Months to 6 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 31
States / cities: Los Angeles, California • Oakland, California • San Diego, California + 21 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone, Dapsone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 43
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Amphotericin B, Lipid-based, Amphotericin B; Drug
Lead sponsor: Liposome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: Torrance, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more

Conditions: HIV Infections, Emphysema, Chronic Obstructive Pulmonary Disease, Pneumocystis
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimethoprim, Sulfamethoxazole, Dapsone; Drug
Lead sponsor: Jacobus Pharmaceutical; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: Itraconazole, Fluconazole; Drug
Lead sponsor: Janssen Pharmaceuticals; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 14 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Leucovorin calcium; Drug
Lead sponsor: U.S. Bioscience; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: West Conshohocken, Pennsylvania

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Gonorrhea
Interventions: Zoliflodacin, high calorie, high fat breakfast; Drug · Other
Lead sponsor: Drugs for Neglected Diseases; Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Syphilis
Interventions: Azithromycin, Benzathine Penicillin, Doxycycline; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 593 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2009
U.S. locations: 7
States / cities: Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 3 more

Conditions: Neisseria Gonorrhoeae Infection
Interventions: Meningococcal Group B Vaccine; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 25 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections, Staphylococcal Infections
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: San Diego, California • Bethesda, Maryland

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Flucytosine, Fluconazole, Amphotericin B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP

Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)

The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection

Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen

Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB

A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS

NeuMoDx PrEDiCTiNG Study Evaluation Plan

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides

Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome

Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center

A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.

Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy

Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin

Azithromycin/Bicillin Syphilis

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine

Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis